UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Cell, 2017-10, Vol.171 (3), p.696-709.e23

2017

Volltextzugriff (PDF)

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.1-9

2009

Volltextzugriff (PDF)

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

JNCI : Journal of the National Cancer Institute, 2012-02, Vol.104 (3), p.228-239

2012

Volltextzugriff (PDF)

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (1), p.143-150

2009

Volltextzugriff (PDF)

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

Cancer research (Chicago, Ill.), 2019-06, Vol.79 (12), p.3100-3111

2019

Volltextzugriff (PDF)

The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration

Molecular cell, 2017-03, Vol.65 (6), p.959-960

2017

Volltextzugriff (PDF)

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Bioconjugate chemistry, 2005-09, Vol.16 (5), p.1282-1290

2005

Volltextzugriff (PDF)

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Molecular cancer therapeutics, 2023-07, Vol.22 (7), p.891-900

2023

Volltextzugriff (PDF)

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Molecular aspects of medicine, 2010-04, Vol.31 (2), p.135-144

2010

Volltextzugriff (PDF)

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Molecular cancer therapeutics, 2004-07, Vol.3 (7), p.763-772

2004

Volltextzugriff (PDF)

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

BMC genomics, 2016-06, Vol.17 (1), p.455-455, Article 455

2016

Volltextzugriff (PDF)

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Clinical cancer research, 2005-06, Vol.11 (12), p.4338-4340

2005

Volltextzugriff (PDF)

Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

Cancer research (Chicago, Ill.), 2019-10, Vol.79 (20), p.5457-5457

2019

Volltextzugriff (PDF)

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Molecular cancer therapeutics, 2005-09, Vol.4 (9), p.1349-1357

2005

Volltextzugriff (PDF)

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

Molecular cancer therapeutics, 2010-03, Vol.9 (3), p.706-717

2010

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.94-100

2009

Volltextzugriff (PDF)

Discovery of a novel class of AKT pleckstrin homology domain inhibitors

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.2621-2632

2008

Volltextzugriff (PDF)

Stereochemical Assignments for All Four Isomers of Dolaproine via Lactam Formation

Synthesis (Stuttgart), 2007-12, Vol.2007 (24), p.3846-3850

2007

Volltextzugriff (PDF)

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

Cancer chemotherapy and pharmacology, 2006-10, Vol.58 (4), p.444-450

2006

Volltextzugriff (PDF)

Inhibiting PI-3-K for glioma therapy

Cell cycle (Georgetown, Tex.), 2009-02, Vol.8 (3), p.335-337

2009

Volltextzugriff (PDF)

CMC Regulatory Considerations for Antibody-Drug Conjugates

Journal of pharmaceutical sciences, 2023-12, Vol.112 (12), p.2965-2980

2023

Volltextzugriff (PDF)

Nicotinanilides as inhibitors of neutrophil chemotaxis

Bioorganic & medicinal chemistry letters, 2002-06, Vol.12 (11), p.1517-1520

2002

Volltextzugriff (PDF)

Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates

AAPS PharmSciTech, 2018-04, Vol.19 (3), p.971-977

2018

Volltextzugriff (PDF)

Nonpeptide αvβ3 antagonists. Part 2: Constrained glycyl amides derived from the RGD tripeptide

Bioorganic & medicinal chemistry letters, 2002-01, Vol.12 (1), p.25-29

2002

Volltextzugriff (PDF)

Nicotinamide N-oxides as CXCR2 antagonists

Bioorganic & medicinal chemistry letters, 2001-07, Vol.11 (14), p.1951-1954

2001

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(59)
Dissertationen
(1)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(30)
Humans
(24)
Animals
(17)
Oncology
(16)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Chemistry
(12)
Mice
(12)
Pharmacology. Drug Treatments
(11)
Physical Sciences
(11)
Cell Line, Tumor
(10)
Pharmacology & Pharmacy
(10)
Chemistry, Organic
(9)
Phosphatidylinositol 3-Kinases - Antagonists & Inhibitors
(8)
Signal Transduction
(8)
Antineoplastic Agents - Pharmacology
(7)
Enzyme Inhibitors - Pharmacology
(7)
Mice, Scid
(7)
Phosphatidylinositol 3-Kinases - Metabolism
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Discovery of a novel class of AKT pleckstrin homology domain inhibitors

Stereochemical Assignments for All Four Isomers of Dolaproine via Lactam Formation

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

Inhibiting PI-3-K for glioma therapy

CMC Regulatory Considerations for Antibody-Drug Conjugates

Nicotinanilides as inhibitors of neutrophil chemotaxis

Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates

Nonpeptide αvβ3 antagonists. Part 2: Constrained glycyl amides derived from the RGD tripeptide

Nicotinamide N-oxides as CXCR2 antagonists

Suchergebnisse filtern